End-of-life measures in Huntington disease

HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning

Noelle E. Carlozzi*, Nicholas R. Boileau, Jane S. Paulsen, Joel S. Perlmutter, Jin-Shei Lai, Elizabeth A Hahn, Michael K. McCormack, Martha A. Nance, David Cella, Stacey K. Barton, Nancy R. Downing

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background and purpose: Huntington disease (HD) is a progressive neurodegenerative disorder. There are no HD-specific measures to assess for end-of-life (EOL) preferences that have been validated for clinical use. The purpose of this study is to demonstrate reliability and validity of three HD-specific EOL measures for use in and clinical research settings. Methods: We examined internal reliability, test–retest reliability, floor and ceiling effects, convergent and discriminant validity, known groups’ validity, measurement error, and change over time to systematically examine reliability and validity of the HDQLIFE EOL measures. Results: Internal consistency and test–retest reliability were > 0.70. The measures were generally free of floor and ceiling effects and measurement error was minimal. Convergent and discriminant validity were consistent with well-known constructs in the field. Hypotheses for known groups validity were partially supported (there were generally group differences for the EOL planning measures, but not for meaning and purpose or concern with death and dying). Measurement error was acceptable and there were minimal changes over time across the EOL measures. Conclusions: Results support the clinical utility of the HDQLIFE EOL measures in persons with HD.

Original languageEnglish (US)
JournalJournal of Neurology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Huntington Disease
Reproducibility of Results
Neurodegenerative Diseases
Research

Keywords

  • End of life
  • HDQLIFE
  • Huntingon disease
  • Reliability
  • Validity

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Carlozzi, Noelle E. ; Boileau, Nicholas R. ; Paulsen, Jane S. ; Perlmutter, Joel S. ; Lai, Jin-Shei ; Hahn, Elizabeth A ; McCormack, Michael K. ; Nance, Martha A. ; Cella, David ; Barton, Stacey K. ; Downing, Nancy R. / End-of-life measures in Huntington disease : HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning. In: Journal of Neurology. 2019.
@article{e0f78c3d27db4923a2c6c53afff6e632,
title = "End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning",
abstract = "Background and purpose: Huntington disease (HD) is a progressive neurodegenerative disorder. There are no HD-specific measures to assess for end-of-life (EOL) preferences that have been validated for clinical use. The purpose of this study is to demonstrate reliability and validity of three HD-specific EOL measures for use in and clinical research settings. Methods: We examined internal reliability, test–retest reliability, floor and ceiling effects, convergent and discriminant validity, known groups’ validity, measurement error, and change over time to systematically examine reliability and validity of the HDQLIFE EOL measures. Results: Internal consistency and test–retest reliability were > 0.70. The measures were generally free of floor and ceiling effects and measurement error was minimal. Convergent and discriminant validity were consistent with well-known constructs in the field. Hypotheses for known groups validity were partially supported (there were generally group differences for the EOL planning measures, but not for meaning and purpose or concern with death and dying). Measurement error was acceptable and there were minimal changes over time across the EOL measures. Conclusions: Results support the clinical utility of the HDQLIFE EOL measures in persons with HD.",
keywords = "End of life, HDQLIFE, Huntingon disease, Reliability, Validity",
author = "Carlozzi, {Noelle E.} and Boileau, {Nicholas R.} and Paulsen, {Jane S.} and Perlmutter, {Joel S.} and Jin-Shei Lai and Hahn, {Elizabeth A} and McCormack, {Michael K.} and Nance, {Martha A.} and David Cella and Barton, {Stacey K.} and Downing, {Nancy R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00415-019-09417-7",
language = "English (US)",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "D. Steinkopff-Verlag",

}

End-of-life measures in Huntington disease : HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning. / Carlozzi, Noelle E.; Boileau, Nicholas R.; Paulsen, Jane S.; Perlmutter, Joel S.; Lai, Jin-Shei; Hahn, Elizabeth A; McCormack, Michael K.; Nance, Martha A.; Cella, David; Barton, Stacey K.; Downing, Nancy R.

In: Journal of Neurology, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - End-of-life measures in Huntington disease

T2 - HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning

AU - Carlozzi, Noelle E.

AU - Boileau, Nicholas R.

AU - Paulsen, Jane S.

AU - Perlmutter, Joel S.

AU - Lai, Jin-Shei

AU - Hahn, Elizabeth A

AU - McCormack, Michael K.

AU - Nance, Martha A.

AU - Cella, David

AU - Barton, Stacey K.

AU - Downing, Nancy R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background and purpose: Huntington disease (HD) is a progressive neurodegenerative disorder. There are no HD-specific measures to assess for end-of-life (EOL) preferences that have been validated for clinical use. The purpose of this study is to demonstrate reliability and validity of three HD-specific EOL measures for use in and clinical research settings. Methods: We examined internal reliability, test–retest reliability, floor and ceiling effects, convergent and discriminant validity, known groups’ validity, measurement error, and change over time to systematically examine reliability and validity of the HDQLIFE EOL measures. Results: Internal consistency and test–retest reliability were > 0.70. The measures were generally free of floor and ceiling effects and measurement error was minimal. Convergent and discriminant validity were consistent with well-known constructs in the field. Hypotheses for known groups validity were partially supported (there were generally group differences for the EOL planning measures, but not for meaning and purpose or concern with death and dying). Measurement error was acceptable and there were minimal changes over time across the EOL measures. Conclusions: Results support the clinical utility of the HDQLIFE EOL measures in persons with HD.

AB - Background and purpose: Huntington disease (HD) is a progressive neurodegenerative disorder. There are no HD-specific measures to assess for end-of-life (EOL) preferences that have been validated for clinical use. The purpose of this study is to demonstrate reliability and validity of three HD-specific EOL measures for use in and clinical research settings. Methods: We examined internal reliability, test–retest reliability, floor and ceiling effects, convergent and discriminant validity, known groups’ validity, measurement error, and change over time to systematically examine reliability and validity of the HDQLIFE EOL measures. Results: Internal consistency and test–retest reliability were > 0.70. The measures were generally free of floor and ceiling effects and measurement error was minimal. Convergent and discriminant validity were consistent with well-known constructs in the field. Hypotheses for known groups validity were partially supported (there were generally group differences for the EOL planning measures, but not for meaning and purpose or concern with death and dying). Measurement error was acceptable and there were minimal changes over time across the EOL measures. Conclusions: Results support the clinical utility of the HDQLIFE EOL measures in persons with HD.

KW - End of life

KW - HDQLIFE

KW - Huntingon disease

KW - Reliability

KW - Validity

UR - http://www.scopus.com/inward/record.url?scp=85067383128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067383128&partnerID=8YFLogxK

U2 - 10.1007/s00415-019-09417-7

DO - 10.1007/s00415-019-09417-7

M3 - Article

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -